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Summary
Small retrospective studies have shown the 
benefit of endovascular treatment with intrasi-
nus thrombolysis (IST) or mechanical thrombec-
tomy (MT) with/without IST (MT+/–IST) in 
cases of multifocal cerebral venous thrombosis 
(CVT).
Our study compares the mortality, functional 
outcome and periprocedural complications 
among patients treated with MT +/– IST versus 
IST alone.
We reviewed clinical and angiographic find-
ings of 63 patients with CVT who received en-
dovascular treatment at three tertiary care cent-
ers. Primary outcome variables were discharge 
mortality and neurological dysfunction, and in-
termediate (three months) and long-term (>six 
months) morbidity. The modified Rankin scale 
(mRS) was used to assess morbidity. mRS ≤1 
was considered a good recovery. Neurological 
dysfunction was rated as neuroscore: 0, normal; 
1, mild (ambulatory, communicative); 2, moder-
ate (non-ambulatory, communicative); and 3, 
severe (non-ambulatory, non-communicative/
comatose).
In patients who received IST alone, presenting 
neurological deficits were comparatively minor 
(p<0.001). When the two groups were adjusted 
for admission neuroscore, there was no statisti-
cal significance between discharge mortality 
[7(21%) versus 4(14%), p=0.228], neurological 
dysfunction (p=0.442), intermediate (p=0.336) 
and long-term morbidity (p=0.988). Patients 
who received MT +/- IST had a higher percent-
age of periprocedural complications without 
reaching statistical significance.
Compared to IST, MT was performed in se-
vere cases with extensive sinus involvement. 
When adjusted for admission neurological dys-
function, both groups had similar mortality and 
discharge neurological dysfunction and similar 
intermediate and long-term morbidity.
Introduction
Cerebral venous thrombosis (CVT) is a rare 
type of stroke (0.5-1% of all strokes) 1. it can be 
a devastating disease with mortality ranging 
between 4.3 and 6.8% in assessment of two 
large databases 2,3. There has been a decline in 
mortality in recent years due to early recogni-
tion and treatment with anticoagulation 3. There 
is modest evidence from three small rand-
omized controlled clinical trials and multiple 
observational studies supporting a role for anti-
coagulation in the treatment of CVT regardless 
of the presence of intracerebral hemorrhage 
(iCh) before the initiation of treatment 1,4. De-
Fazeel M. Siddiqui  Mechanical Thrombectomy versus Intrasinus Thrombolysis for Cerebral Venous Sinus Thrombosis...
337
spite adequate anticoagulation, patients can 
still have a poor clinical outcome especially in 
cases with large and extensive, rapidly pro-
gressing or multifocal thrombosis 1,4. For such 
cases, endovascular delivery of fibrinolytic 
agents with or without mechanical disruption 
has been successfully used in multiple case re-
ports and smaller case series 1, 5-8. The theoreti-
cal advantages of this treatment include direct 
delivery of fibrinolytic agent into the clot mini-
mizing systemic side-effects 6.
Angiojet, a rheolytic thrombectomy system 
(mEDRAD, inc, warrendale, PA, usA) is the 
most commonly used device for mechanical 
thrombectomy (mT) 6,9-22, followed by the Pe-
numbra thromboaspiration system (Penumbra, 
inc, Alameda, CA, usA) 23-27 and the mERCi 
(mechanical Embolus Removal in Cerebral 
ischemia) clot retrieval device (Concentric 
medical, mountain View, CA, usA) 28. me-
chanical methods result in more rapid recanali-
zation and increase the surface of the thrombus 
exposed to thrombolytics 6. 
There is only one non-randomized compari-
son between anticoagulation versus isT and its 
findings suggested that local thrombolysis may 
be more effective than systemic heparin in se-
lected cases 29. This study did not employ me-
chanical methods. A prospective series on 20 
patients with severe CVT who mostly received 
mT with or without isT (mT +/– isT) showed 
higher mortality and post treatment iCh and 
advised caution in using endovascular methods 
6. we performed this study to compare the mor-
Table 1  Comparison of demographic and clinical characteristics of patients who received MT+/-IST versus IST alone.
Variables Mechanical thrombectomy
with/without continuous
thrombolytic infusion
(N=34) 
Intrasinus
thrombolysis
(N=29) 
P value
Age (median, range) 35 (12-57) 32 (4-61) 0.978
Female (%) 26 (77) 20 (69) 0.576
Presenting symptoms
– headaches (%)
– seizures (%)
  sE (%)
– FnD (%)
– Encephalopathy/coma (%)
34 (100)
17 (50)
4 (11)
28 (82)
21 (62) 
26 (90)
10 (35)
0 (0)
18 (62)
9 (31) 
0.092
0.307
0.118
0.091
0.023*
Prothrombotic conditions (%) 15 (44) 17 (59) 0.315
Venous infarction (%)
– non-hemorrhagic (%)
– hemorrhagic (%)
25 (74)
8 (24)
19 (56) 
13 (45)
4 (14)
10 (35) 
0.038*
0.358
0.129 
Reason for procedure
– Extensive involvement of sinuses with
 altered  mental status/coma (%)
– Deterioration of symptoms despite being
 on anticoagulation (%)
– large space-occupying lesions, such as
 edema or (hemorrhagic) infarcts (%)
– †other/unspecified (%)
25 (74)
24/33 (72)
25 (74)
4 (11) 
10 (35)
6/10 (60)
9 (31)
14 (46) 
Admission neurological deficit 
– normal (%)
– mild (%)
– moderate (%)
– severe (%)
0 (0)
6 (17)
4 (12)
24 (71) 
5 (17)
11 (38)
7 (24)
6 (21) 
0.001*
sD= Standard deviation; sE= Status epilepticus; FnD= Focal neurological deficits
* Statistically significant
† All cases in the ‘Other’ category had persistent progressive headache or worsening papilloedema.
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tality and morbidity, angiographic recanaliza-
tion and periprocedural complications between 
patients who received mT +/– isT versus isT 
alone. 
Methods
we identified 63 patients with CVT who re-
ceived endovascular treatment at three large 
tertiary care centers. (university of Texas 
southwestern medical Center, Dallas, Texas, 
usA, Academic medical Center, university of 
Amsterdam, netherlands and university of 
California, los Angeles, California, usA). This 
study was approved by local institutional re-
view boards for medical record chart review. 
Patient selection
Academic Medical Center, University of 
Amsterdam, Netherlands: 27 patients, treated 
between 1999 and 2012 were identified from a 
prospective database (mT=24, isT alone=3). 
All patients had an assumed poor prognosis 
because of altered mental status or coma, 
straight sinus thrombosis, or large space-occu-
pying lesions, such as edema or (hemorrhagic) 
infarcts. Twenty patients have been previously 
described 6.
University of Texas Medical Center, Dallas 
Texas, USA: 33 patients were identified retro-
spectively from hospital databases between 
1995 and 2012 (mT=7, isT alone=26). Twenty-
three cases were previously published 24,29-31. 
The decision to perform endovascular inter-
vention was operator-dependent.
university of California, los Angeles, Cali-
fornia, usA: three patients were identified ret-
rospectively from hospital databases from 1999 
to 2012 (mT=3). Two cases were previously 
published 20. The decision to perform endovas-
cular intervention was operator-dependent.
Diagnosis
The diagnosis of CVT was confirmed by 
mRi and mR venography, CT venography, or 
conventional angiography. The pretreatment 
CT or mRi scans were assessed for midline 
shift and lesion size, measured as the surface on 
the image with the largest diameter of the le-
sion on the last available scan before throm-
bolysis. Any cerebral lesion with CT or mRi 
signals compatible with blood was defined as 
hemorrhagic infarct. 
Table 2  Description of mechanical thrombectomy devices and thrombolytic agents.
Variables Mechanical thrombectomy
with/without continuous
thrombolytic infusion
(n=34)
Intrasinus thrombolysis
 (n=29)
Type of device
 Angiojet
 Penumbra 
 mERCi with Penumbra
 balloon angioplasty
28
3
1
2
n/A
Type of thrombolytics
 urokinase
 tPA
 Tirofiban
 none
23
4
2
7
23
6
0
n/A
Continuous thrombolysis
 urokinase
 tPA
 Tirofiban
25
80,000-100000/h
1 mg/h
0.5 mcg/kg/h
(in conjunction with tPA)
29
80000-100000/h
1 mg/h
n/A
Duration of continuous thrombolysis 6-96 h 8-96h
n/A=Not applicable
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Endovascular methods: isT was performed 
by introducing a catheter via the internal jugu-
lar or femoral vein and advancing it into a 
frontal position in the superior sagittal sinus 
while the thrombus was dissolved with throm-
bolytic boluses [urokinase or tissue plasmino-
gen activator (tPA)]. other sinuses were ap-
proached if needed and boluses were given. in 
most cases, the catheter was left in situ, and 
thrombolytics were infused locally for variable 
periods of time depending upon the rate of re-
canalization. sinus recanalization was exam-
ined by contrast injection through the throm-
bolysis catheter or by intra-arterial angiogra-
phy. Recanalization was rated as no recanali-
zation or technical failure, partial or incom-
plete recanalization (contrast visible but lumen 
too narrow) and complete or near complete 
recanalization. heparin was continued during 
thrombolytic therapy. in patients who received 
mT, thrombosuction/thrombectomy was per-
formed using Angiojet, Penumbra system or 
mERCi clot retrieval device.
Outcome variables: Primary outcome varia-
bles were discharge mortality and neurological 
dysfunction, and intermediate (three months) 
and long term (>six months) morbidity utiliz-
ing modified Rankin scores (mRs) [(0=com-
plete recovery; 6=death)]. mRs ≤1 was consid-
ered a good recovery. neurological dysfunction 
was assessed on admission and discharge and 
was rated as neuroscore: 0, normal; 1, mild (am-
bulatory and communicative); 2, moderate 
(non-ambulatory but communicative); 3, severe 
(non-ambulatory and non-communicative/
comatose). This scale was previously described 
by wasay et al. in a similar population 29. The 
reason for using a non-standardized simple 
scale instead of a detailed disability scale is to 
minimize the variability in outcome assessment 
from chart review 30. secondary outcome varia-
bles included periprocedural complications 
(defined as complications within a month of 
procedure), recanalization, delayed complica-
tions and recurrence rates. Recurrence was de-
fined as clinical (new symptoms or recurrence 
Table 3  Comparison of primary outcome variables between MT±IST versus IST alone.
Variables Mechanical thrombectomy
with/without continuous
thrombolytic infusion
(n=34) 
Intrasinus
thrombolysis
(n=29) 
p1
(unadjusted) 
p2
(adjusted) 
Death (%) 7 (21%) 4 (14%) 0.526 0.248† 
Discharge
neurological deficit 
0.002* 0.442‡ 
 normal (%) 6 (22%) 17 (68%) 
 mild (%)  13 (48%) 6 (24%) 
 moderate (%)  7 (26%) 2 (8%) 
 severe (%) 1 (4%) 0 (0%) 
mRS (3 months) 0.060 0.336‡
 lost to follow-up 2 8
 mRs≤1 (%) 17 (68%) 16 (94%) 
 mRs>1(%)  8 (32%) 1 (6%) 
mRS(>6 months) 0.378 0.988‡
 lost to follow-up 5 13
 mRs≤1(%)  16 (73%) 11 (92%) 
 mRs>1(%)  6 (27%) 1 (8%) 
mRs=Modified Rankin score; neuroscore-D=Discharge neuroscore
p1: *p-value represents Wilcoxon-rank sum test and rest of p-values are from Fisher’s exact test
p2: p-values adjusting for neuroscore at admission
† p-value is from Cox regression adjusting for neuroscore at admission
‡ p-value is from logistic regression adjusting for neuroscore at admission
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of previous symptoms) and neuroimaging 
(mRi/mRV) evidence of recurrent or more ex-
tensive CVT.
Statistical analysis
we used Fisher’s exact test to compare the 
categorical variables and wilcoxon rank sum 
test to compare continuous or ordinal variables 
between two groups of mT±isT and isT alone. 
log-rank test was performed to determine if 
there was a significant difference in patient sur-
vival between the two groups. Cox regression 
analysis was used to investigate if time was sig-
nificantly different between the two groups af-
ter controlling the effect of admission neuro-
score. logistic regression analysis was conduct-
ed to examine if there were significant differ-
ences in discharge neurological deficit, dichoto-
mized mRs score (mRs≤1 vs. mRs>1) at three 
months and >six months between two groups 
after controlling the effect of admission neuro-
score. statistical analyses were two-tailed and 
considered significant if p<0.05.
Results
sixty-three patients underwent endovascular 
treatment for CVT. Thirty-four patients re-
ceived mT +/– isT and 29 patient received isT 
alone. Table 1 provides a comparison of demo-
graphic and clinical characteristics between pa-
tients who received mT +/– isT versus isT 
alone. The most common presenting symptom 
was headache in both groups. Patients who re-
ceived mT +/– isT had a higher percentage of 
seizures, focal neurological deficits, encepha-
lopathy or coma. They also had significantly 
higher admission neuroscores. The reason for 
an endovascular procedure was well-defined in 
patients who received mT +/– isT and includ-
ed extensive involvement of the sinuses with 
altered mental status or coma, deterioration of 
symptoms despite being on anticoagulation, 
and large space-occupying lesions, such as ede-
ma or (hemorrhagic) infarcts. in patients who 
received isT only, reasons were less defined 
and operator-dependent (Table 1).
The term anticoagulation failure was loosely 
used for all patients that deteriorated clinically 
on an adequate dose of heparin or oral antico-
agulants. The timing of anticoagulation prior to 
the procedure was variable and ranged from no 
anticoagulation to nine days. Exceptions were 
two patients who had a relapse of their symp-
toms after three months of adequate anticoag-
ulation therapy and were considered candi-
dates for endovascular intervention.
Five patients received heparin only for a few 
hours before endovascular intervention mainly 
during transfer from a peripheral facility to a 
tertiary care center. Eleven patients received 
heparin for the first time in the angiography 
suite. Twenty patients had no documentation of 
prior use of anticoagulation before the proce-
dure.
Mechanical thrombectomy with/without 
intrasinus thrombolysis
Angiojet was the most commonly used mT 
device (28 patients), followed by Penumbra 
and mERCi. Two patients received angioplasty 
only. Twenty-seven patients received isT dur-
ing the procedures. Twenty-five patients re-
ceived continuous thrombolytic infusion. urok-
inase was the most commonly used thrombo-
lytic agent followed by tPA. Duration of throm-
bolysis varied from six to 96 hours (Table 2).
Figure 1  kaplan meyer curve depicting survival rates be-
tween mT±isT versus isT alone at discharge.
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Two patients received Tirofiban (Aggrastat, 
medicure Pharma) infusion in conjunction with 
tPA. Tirofiban is a glycoprotein iib/iiia inhibi-
tor that has been anecdotally used in ischemic 
stroke mechanical interventions to maintain 
blood flow through channels opened by me-
chanical thrombectomy especially in the setting 
of hypercoagulable states 30,32,33.
Intrasinus thrombolysis: All patients in the 
thrombolysis group received continuous infu-
sion for variable duration (8-96 h). The most 
commonly used thrombolytic agent was uroki-
nase followed by tPA (Table 2).
Outcome: There was no statistically signifi-
cant difference in adjusted discharge mortality 
between the two groups (7(21%) versus 
4(14%), p=0.248) [Table 3, Figure 1]. The unad-
justed discharge neuroscore was significantly 
higher in patients who received mT (p=0.002). 
however, when adjusted for admission neuro-
score using a logistic regression model, the dif-
ference was not significant (p=0.442). 
There was no statistically significant differ-
ence in the adjusted intermediate and long-
term morbidity between two groups (Table 3).
Periprocedural complications
There was a higher percentage of periproce-
dural complications in patients who received 
mT+/–isT (not significant, P=0.299) (Table 4). 
There were five new hemorrhagic infarctions 
and three enlargements of prior hemorrhages 
in the mT +/– isT group compared to four new 
hemorrhagic infarctions in the isT group. Com-
plications secondary to direct catheter manipu-
lations were more prevalent in the mT +/– isT 
group (Table 4).
Table 4  Comparison of secondary outcome variables between MT±IST versus IST alone.
Variables Mechanical thrombectomy
with/without continuous 
thrombolytic infusion
N=34
Intrasinus thrombolysis
N=29
hospital stay (median, range) 11 (1-53) 9 (2-30) 0.923
 Peri-procedural complications 14(41) 8(28) 0.299
 (%) 7 4
 Death 5 4
 new iCh 3 0
 worsening of previous iCh
Catheter-related complications 0 1
 Retroperitoneal  hemorrhage 1 0
 Catheter tip fracture 1 0
 Perforation of sinus 1 0
 groin hematoma 1 0
 Formation of bilateral inguinal
 aneurysm
Recanalization rates (n=33) (n=10)‡ 0.690
 none*(%) 4(12) 0(0)
 Partial (%) 13(33) 5(50)
 near to full improvement†(%) 16(50) 5(50)
Recurrence (%) 1(3) 3(10) 0.286
* One angioplasty and two AngioJet cases
† All Penumbra/MERCI cases
‡ The 19 missing patients had either partial or complete recanalization but not well-documented
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Recanalization rates: Recanalization rates 
were available in 33 mT +/– isT patients and 
ten isT alone patients. There was no significant 
difference between the two groups (Table 4).
Recurrence: The recurrence rate of CVT was 
10% (n=3) in the isT alone group and 3% 
(n=1) in the mT +/– isT group (p=0.293). Three 
patients with recurrence presented within three 
months of discharge while one patient present-
ed after two and a half years.
Delayed complications: Three patients in the 
mT +/– isT group developed pseudotumor 
cerebri with two of them requiring ventricu-
loperitoneal shunts. All three had either partial 
or no recanalization after the procedure. in 
three patients from the isT alone group, isT 
was performed to treat pseudotumor cerebri 
but they continued to have persistent head-
aches and high intracranial pressure at long-
term follow-up. 
one patient developed seizures requiring 
medications. All four patients had adequate re-
canalization after the procedure. 
Discussion
The first use of isT was reported by scott et 
al. in 1988. They catheterized the sagittal sinus 
via a frontal burr hole and infused urokinase 
over an eight-hour period, followed by excel-
lent recovery 34.
Dowd et al. reported the first case of using 
an mT device to treat CVT. They applied an 
Angiojet rheolytic system for thrombectomy 
followed by intrasinus infusion of urokinase for 
two days. since then several case reports and 
series have been published on the successful 
use of either an mT device alone or in combi-
nation with direct intrasinus infusion of throm-
bolytic agents 8. 
According to the American heart Associa-
tion guidelines for diagnosis and management 
of CVT, the use of such procedures is recom-
mended only if clinical deterioration occurs de-
spite use of anticoagulation, or if the patient 
develops mass effect from a venous infarction 
or iCh that causes intracranial hypertension 
resistant to standard therapies 1. however, there 
is no proper definition or time limit for antico-
agulation failure, as evident from the findings 
of our study. hence, there is variability in the 
timing to intervene in patients who are already 
on therapeutic anticoagulation. in a recently 
published study, mohammadian et al. defined 
anticoagulation failure as clinical deterioration 
after at least four days of full anticoagulation 
with heparin (or 48 hours in patients with in-
volvement of more than one sinus) 7.
There is only one non-randomized compari-
son between heparin treatment and isT for the 
treatment of CVT. its findings showed that isT 
may offer some benefit over heparin treatment 
although the study had several limitations 30. A 
clinical trial to compare endovascular treat-
ment (all modalities) versus heparin has been 
set-up and is currently recruiting patients 35.
our study offers a non-randomized compari-
son between mT +/– isT versus isT alone. The 
use of mT versus isT is institute and operator-
dependent. in our study there was a significant 
difference in the choice of treatment between 
European and usA institutes. The cases re-
ceived from the Academic hospital of Amster-
dam, netherlands primarily used mT in most 
patients (24/27), whereas very few cases of at-
tempted mT were found in the uTsw and 
uClA institutional archives. Though theoreti-
cally, mT appears to be a better option than 
isT alone, clinical data are lacking to support 
this hypothesis. soleu et al., in a small retro-
spective series of 31 patients who received all 
three treatment options (heparin versus isT 
versus mT), found mT to be more beneficial 
than isT with less hemorrhage risk. 
They did not use isT in conjunction with mT 
36. Proponents of both treatment modalities 
have published case series to advocate local 
thrombolysis or mechanical thrombectomy as 
safe first or second line treatment options for 
severe CVT 7,10. many interventionalists fear 
that the procedure-related complications with 
mT devices may cause more harm than benefit 
to the patient. older devices like Angiojet are 
bulky and stiff and had potential to cause sinus 
perforation. The large size of the Angiojet pre-
vents it from accessing smaller sinuses minimiz-
ing its utility. This fear has been overcome in 
the recent years with the advent of newer tech-
niques and devices such as Penumbra and 
mERCi. 
our study also indicates that in most insti-
tutes, mT is reserved mostly for complicated 
cases with severe neurological deficits. in mild-
er cases isT is preferred. 
our study offers a modest comparison be-
tween two endovascular treatment groups in a 
diverse population. when adjusted for injury 
severity at admission, both groups had similar 
discharge, intermediate and long-term mortali-
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ty and morbidity. Though periprocedural com-
plications and recanalization rates were not sig-
nificantly different between the two groups, di-
rect catheter-related complications were more 
common in the mT group probably secondary 
to the more excessive manipulations required 
with thrombectomy or thromboaspiration.
our study has several limitations. it is a ret-
rospective study with non-randomized treat-
ment groups. There is a hospital/operator pref-
erence for the treatment modality. The number 
of patients is relatively small, although larger 
than any previously published series on mT. 
we used a simplified scale to monitor outcome 
at discharge which is non-standardized. A large 
number of patients are lost to follow-up for 
long-term evaluations. There is variability of 
devices, thrombolytic agents, and the duration 
of continuous thrombolytic infusion.
Conclusion
our study compared two endovascular mo-
dalities for the treatment of severe CVT. both 
treatment options have similar discharge, inter-
mediate and long-term mortality and morbidi-
ty. however, device-related complications were 
more prevalent in the mT group. based on our 
data, the decision to use endovascular options 
for the treatment of CVT is operator and insti-
tute-dependent. The term ‘anticoagulation fail-
ure’ is vague and causes unnecessary confusion 
in decision-making. There is a preference to use 
isT alone in milder cases of CVT and mT +/- 
isT in severe cases, probably caused by fear of 
complications with mT devices. newer devices 
like Penumbra and mERCi have better safety 
profiles but data on their application for CVT 
is limited.
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